Melatonin reduces oxidative catastrophe in neurons and glia

Activitas Nervosa Superior Rediviva

Volumn 52, Issue 2, 2010, Pages 93-103

  Reiter, Russel J ^a   Reyes Gonzales, Marcus ^a   Fuentes Broto, Lorena ^a   Tan, Dun Xian ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Free radicals; Glia; Melatonin; Neurodegenerative diseases; Neurons; Oxidative stress; Reactive nitrogen species; Reactive oxygen species

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; FREE RADICAL; MELATONIN; N1 ACETYL 5 METHOXYKYNURAMINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; ASTROCYTE; BRAIN; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DEGENERATIVE DISEASE; DEMENTIA; GLIA CELL; HUMAN; HUNTINGTON CHOREA; NERVE CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PINEAL BODY; REVIEW; SPINAL CORD;

EID: 84865193621     PISSN: 1337933X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (155)

1. Acuna-Castroviejo D, Coto-Montes A, Monti MG, Ortiz GG, Reiter RJ (1997). Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. 60: PL23-29.
2. Acuna-Castroviejo D, Escames G, Leon J, Carayo A, Khaldy H (2003). Mitochondrial regulation by melatonin and it metabolites. Adv Exp Biol Med. 527: 549-557.
3. Adi N, Mash DC, Ali Y, Singer C, Shehadeh L, Papapetropoulos S (2010). Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Med Sci Monit. 16: BR 61-7.
4. Arendt J, Bojkowski C, Franey C, Wright J, Marks V (1985). Immunoassay of 6-hydroxy melatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab. 60: 1166-1173.
5. Arendt J, Wirz-Justice A, Bradtke J (1978). Annual rhythm of serum melatonin in man. Neurosci Lett. 7: 327-330.
6. Bandyopadhyay D, Biswas K, Bandyopadhyay U, Reiter RJ, Banerjee AK (2000). Melatonin protects against stress-induced gastric lesions by scavenging hydroxyl radicals. J Pineal Res. 29: 143-151.
7. Barlow-Walden LR, Reiter RJ, Abe M, Pablos M, Menendez-Pelaez A, Chen LD et al. (1995). Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int. 26: 497-502.
8. Baydas G, Reiter RJ, Nedzvetski VS, Nerush PA, Kirichenko SV (2002). Altered glial fibrillary acidic protein content and its degradation in the hippocampus, cortex and cerebellum of rats exposed to constant light: reversal by melatonin. J Pineal Res. 33: 134-139.
9. Bendz LM & Scales AC (2010). Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder. Ann Pharmacother. 44: 185-191.
10. Benitez-King G (2006). Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res. 40: 1-9.
11. Benitez-King G, Ramirez-Rodriguez G, Ortiz L, Meza I (2004). The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord. 3: 515-533.
12. Betarbet R & Greenamyre JT (2007). Parkinson's disease: animal models. Handb Clin Neurol. 83: 265-287.
13. Blanchard B, Pompon D, Ducrocq C (2000). Nitrosation of melatonin by nitric oxide and peroxynitrite. J Pineal Res. 29: 184-192.
14. Bromme HJ, Morke W, Peschke E, Ebelt H, Peschke, D (2000). Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. J Pineal Res. 29: 201-208.
15. Browne SE & Beal MF (2006). Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal. 8: 2061-2073.
16. Brusco LI, Marquez M, Cardinali DP (1998). Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J Pineal Res. 25: 260-263.
17. Bubenik GA (2001). Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol Signals Recept. 10: 350-366.
18. Cabrera J, Reiter RJ, Tan DX, Qi W, Sainz RM, Mayo JC et al. (2000). Melatonin reduces oxidative neurotoxicity due to quinobinic acid: in vitro and in vivo findings. Neuropharmacology. 39: 507-514.
19. Cardinali DP, Brusco LI, Liberczuk C, Furio AM (2002b). The use of melatonin in Alzheimer's disease. Neuroendocrinol Lett. 23(Suppl 1): 20-23.
20. Cardinali DP, Brusco LI, Lloret SP, Furio AM (2002a). Melatonin in sleep disorders and jet-lag. Neuroendocrinol Lett. 23(Suppl 1): 9-13.
21. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Maurino S, Reiter RJ et al. (2004). Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine and/or paracrine substance. FASEB J.18(3): 537-539.
22. Ceraulo L, Ferrugia M, Tesoriere L, Segreto S, Livrea MA, Turco Liveri V (1999). Interactions of melatonin with membrane models: portioning of melatonin in AOT and lecithin reversed micelles. J Pineal Res. 26: 108-112.
23. Cervantes M, Morali G, Letechipia-Vallejo G (2008). Melatonin and ischemia-reperfusion injury of the brain. J Pineal Res. 45: 1-7.
24. Chetsawang J, Govitrapong P, Chetsawang B (2007). Melatonin inhibits MPP+-induced caspase-mediated death pathway and DNA fragmentation factor-45 cleavage in SK-N-SH cultured cells. J Pineal Res. 43: 115-120.
25. Chiueh C, Miyake H, Peng MT (1993). Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol. 60: 251-258.
26. Crespo-Biel N, Canudas A, Pallas M (2007). Kainate induces AKT, ERK and cdk5/GSK-3β pathway deregulation, phosphorylates tau protein in the mouse hippocampus. Neurochem Int. 50: 435-442.
27. Cummings JL & Cole G (2002). Alzheimer disease. J Am Med Assoc. 287: 2335-2338.
28. Das A, McDowell M, Pava MJ, Smith JA, Reiter RJ, Woodward JJ et al. (2010). The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-α toxicity involves membrane melatonin receptors. J Pineal Res. 48: 157-169.
29. Deng YQ, Xu GG, Duan P, Zhang Q, Wang JZ (2006). Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol Sin. 26: 519-526.
30. Dong W, Huang F, Fan W, Cheng S, Chen Y, Zhang W et al. Differential effects of melatonin on amyloid-β peptide25-35 induced mitochondrial dysfunction in hippocampal neurons at different states of culture. J Pineal Res. 48(2): 117-125.
31. Feng Z, Qin C, Chang Y, Zhang JT (2006). Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Rad Biol Med. 40: 101-109.
32. Fukuda T, Akiyama N, Ikeganir M, Takahashi H, Sasaki A, Oka H et al. (2010). Expression of hydroxyindole-O-methyltransferase enzyme in the human central nervous system and in pineal parenchymal tumor cells. J Neuropathol Exp Neurol. 69: 498-510.
33. Hardeland R (2005). Antioxidant protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 27: 119-130.
34. Hardeland R, Tan DX, Reiter RJ (2009). Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res. 47: 109-126.
35. Harman D (2003). The free radical theory of aging. Antioxd Redox Signal. 5: 557-561.
36. Hoffman RA & Reiter RJ (1965). Pineal gland: influence on gonads of male hamsters. Science. 148: 1609-1611.
37. Hoppe JB, Frozza RL, Horn AP, Comiran RA, Bernardi A, Campos MM et al. (2010). Amyloid-β neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3β, tau and neuroinflammation. J Pineal Res. 48: 230-238.
38. Hulsebosch CE (2008). Gliopathy ensures persistent inflammation and chronic pain after spinal cord injury. Exp Neurol. 214: 6-9.
39. Hulsemann M (1968). Vergleichende histologische untersuchungen uber das vorkommen von Gliafasern in de epiphysis cerebri von Saugetieren. Acta Anat. 66: 249-278.
40. Inzelberg R, Schechtman E, Paleacu D (2002). Onset age of Parkinson disease. Am J Med Genet. 111: 459-460.
41. Jellinger KA (2008). Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegen Disord. 5: 118-121.
42. Jimenez-Jorge S, Guerrero JM, Jimenez-Caliani AJ, Naranjo MC, Lardone PJ, Carrillo-Vico A et al. (2007). Evidence for melatonin synthesis in rat brain during development. J Pineal Res. 42(3): 240-246.
43. Jou MJ (2008). Pathophysiological and pharmacological implications of mitochondria-targeted reactive oxygen species generation in astrocytes. Adv Drug Deliv Rev. 60: 1512-1526.
44. Jou MJ, Peng TH, Hsu LF, Jou B, Reiter RJ, Yang CM et al. (2010). Visualization of melatonin's multiple mitochondrial levels of protection against mitochondrial Ca2+ mediated permeability transition and beyond in rat brain astrocytes. J Pineal Res. 48: 20-38.
45. Jou MJ, Peng TI, Reiter RJ, Jou SB, Wu HY, Wen ST (2004). Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res. 37: 55-70.
46. Kappers JA (1960). The development, topographical relations and innervation of the epiphysis cerebri in the albino rat. Z Zellforsch. 52: 163-215.
47. Kaur C, Sivakumar V, Ling EA (2010). Melatonin protects periventricular white matter from damage due to hypoxia. J Pineal Res. 48: 185-193.
48. Khaldy H, Escames G, Leon J, Bikjdaouene L, Acuna-Castroviejo D (2003). Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DNA depletion. Neurobiol Aging. 24: 491-500.
49. Kim DH, Kim JM, Park SJ, Lee S, Yoon BH, Ryu JH (2010). Early activated microglia play a role in transient forebrain ischemiainduced neural precursor proliferation in the dentate gyrus of mice. Neurosci Lett. 475: 74-79.
50. Kim MJ, Kim HK, Kim BS, Yim SV (2004). Melatonin increases cell proliferation in the dentate gyrus of maternally separated rats. J Pineal Res. 37: 193-197.
51. King TS, Richardson BA, Reiter RJ (1981). Age-associated changes in pineal serotonin N-acetyltransferase activity and melatonin content in the male gerbil. Endocr Res Commun. 8: 253-262.
52. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX (2009). Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med. 15: 43-50.
53. Lahiri DK, Chen DM, Lahiri P, Bondy S, Greig NH (2005). Amyloid, cholinesterase, melatonin and their roles in aging and neurodegenerative conditions. Ann NY Acad Sci. 1056: 430-449.
54. Lambeth JD (2007). Nox enzymes, ROS and chronic disease: an example of antagonistic pleiotropy. Free Rad Biol Med. 43: 332-347.
55. Lauterbach EC, Victoroff J, Coburn KL, Shillcult SD, Doonan SM, Mendez MF (2010). Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci. 22: 8-18.
56. Lee HP, Zhu XW, Casadesus RJ, Castellani RJ, Nunomura A, Smith MA et al. (2010a). Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother. 10: 1201-1208.
57. Lee SI, Jeong SR, Kang YM, Han DX, Jin BK, Namgung U et al. (2010b). Endogenous expression of interleukin-4 regulates macrophage activation and confines cavity formation after traumatic spinal cord injury. J Neurosci Res. 88: 2409-2419.
58. Leon J, Acuna-Castroviejo D, Escames, G, Tan DX, Reiter RJ (2005). Melatonin mitigates mitochondrial malfunction. J Pineal Res. 38: 1-9.
59. Leon J, Acuna-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ (2004). Melatonin and mitochondrial function. Life Sci. 75: 765-790.
60. Leston J, Harthe C, Brun J, Mottolese C, Mertens P, Sindou M et al. (2010). Melatonin is released in the third ventricle in humans: a study of movement disorders. Neurosci Lett. 469: 294-297.
61. Maldonado MD, Murillo F, Terron MP, Flores LJ, Tan DX, Manchester LC et al. (2007). The potential of melatonin in reducing morbidity/mortality after craniocerebral trauma. J Pineal Res. 42: 1-11.
62. Mancuso M, Orsucci D, Lo Gerfo A, Calsolaro V, Siciliano G (2010). Clinical features and pathogenesis of Alzheimer's disease: involvement of mitochondria and mitochondrial DNA. Adv Exp Biol Med. 685: 34-44.
63. Manda K & Reiter RJ (2010). Melatonin maintains adult neurogenesis and cognitive functions after irradiation. Progr Neurobiol. 90: 60-68.
64. Manda K, Ueno M, Anzai K (2009). Cranial irradiation-induced inhibition of neurogenesis in hippocampal dentate gyrus of adult mice: attenuation by melatonin pretreatment. J Pineal Res. 46: 71-78.
65. Martin M, Macias M, Escames G, Leon J, Acuna-Castroviejo D (2000). Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J. 14: 1677-1679.
66. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D et al. (2003). Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem. 85: 1101-1108.
67. Maurizi CP (2003). The puzzle of where cerebrospinal fluid is absorbed: new pieces. Med Hypotheses. 60: 102-103.
68. Maurizi CP (2010). Choroid plexus portals and a deficiency of melatonin can explain the neuropathology of Alzheimer's disease. Med Hypotheses. 74: 1059-1066.
69. Mayo JM, Sainz RM, Tan DX, Antolin I, Rodriguez C, Reiter RJ (2005). Melatonin and Parkinson's disease. Endocrine. 27: 169-179.
70. Menendez-Pelaez A & Reiter RJ (1993). Distribution of melatonin in mammalian tissues: relative importance of nuclear verses cytosolic localization. J Pineal Res. 15: 59-69.
71. Mennenga K, Ueck M, Reiter RJ (1991). Immunohistological localization of melatonin in the pineal gland and retina of the rat. J Pineal Res. 10: 159-164.
72. Mess B & Trentini GP (1974). Melatonin level in cerebrospinal fluid and choroid plexus following intravenous administration of the labeled compound. Acta Physiol Acad Sci Hung. 45: 25-31.
73. Milano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP (2008). Melatonin to prevents migraine or tension-type headache in children. Neurol Sci. 29: 285-287.
74. Molina-Carballo A, Munoz-Hoyos A, Reiter RJ, Sanchez-Forte M, Moreno-Madrid F, Rufo-Campos M et al. (1997). Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years' experience. J Pineal Res. 23: 97-105.
75. Ohira K, Hagihara H, Toyama K, Takao K, Kanai M, Funakoshi H et al. (2010). Expression of tryptophan 2, 3-dioxygenase in mature granule cells of the adult mouse dentate gyrus. Mol Brain. 3(1): 26.
76. Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ et al. (2009). Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res. 47: 82-96.
77. Olivier P, Fontaine RH, Loron G, Van Steenwinckel J, Biran V, Massonneau V et al. (2009). Melatonin promotes oligodendroglial maturation of injured white matter in neonatal rats. PLoS One. 4: e7128.
78. Ortiz GG, Crespo-Lopez ME, Moran-Moguel C, Garcia JJ, Reiter RJ, Acuna-Castroviejo D (2001). Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuroendocrinol Lett. 22: 101-108.
79. Pablos MI, Agapito MT, Gutierrez R, Recio JM, Reiter RJ, Barlow-Walden L et al. (1995). Melatonin stimulates the activity of the detoxifying enzyme glutathione peroxidase in several tissues of chicks. J Pineal Res. 19: 111-115.
80. Pablos MI, Reiter RJ, Ortiz GG, Guerrero JM, Agapito MT, Chuang JI et al. (1998). Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem Int. 32: 69-75.
81. Pang SF, Tsang CW, Hong GX, Yip PC, Tang PL, Brown GM (1990). Fluctuation of blood melatonin concentrations with age: result of changes in pineal melatonin secretion. J Pineal Res. 8: 179-192.
82. Pappolla MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J et al. (2000). An assessment of the antioxidant and antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm. 107: 203-221.
83. Pappolla MA, Simovich MJ, Bryant-Thomas T, Chyan YJ, Poeggeler B, Dubocovich M et al. (2002). The neuroprotective activities of melatonin against Alzheimer beta-protein are not mediated by melatonin membrane receptors. J Pineal Res. 32: 135-142.
84. Paradies G, Petrosillo G, Paradies V, Reiter RJ, Ruggiero FM (2010). Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res. 48: 297-310.
85. Pelham R (1975). A serum melatonin-rhythm in chickens and its abolition by pinealectomy. Endocrinology. 96: 543-546.
86. Pelham R, Vaughan GM, Sandock KL, Vaughan MK (1973). Twenty-four-hour cycle of a melatonin-like substance in the plasma of human males. J Clin Endocrinol Metab. 37: 341-344.
87. Perry G, Castellani RJ, Hirai K, Smith MA (1998). Reactive oxygen species mediate cellular damage in Alzheimer's disease. J Alzheimer's Dis. 1(1): 45-55.
88. Quay WB (1965). Histological structure and cytology of the pineal organ in birds and mammals. Progr Brain Res. 10: 49-86.
89. Quay WB (1970a). Endocrine effects of the mammalian pineal. Am Zool. 10: 237-46.
90. Quay WB (1970b). Pineal structure and composition of the orangutan (Pongo pygmaeus). Anat Rec. 168: 93-104.
91. Rahman SA, Kayumov L, Shapiro CM (2010). Antidepressant action of melatonin in the treatment of delayed sleep phase syndrome. Sleep Med. 11: 131-136.
92. Ramirez-Rodriguez G, Klempin F, Babu H, Benitez-King G, Kempermann G (2009). Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. Neuropsychopharmacology. 46: 71-78.
93. Reddy PH & Beal MF (2005). Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev. 49: 618-623.
94. Reiter RJ (1973). Pineal control of a seasonal reproductive rhythm in male golden hamsters exposed to natural daylight and temperature. Endocrinology. 92: 423-430.
95. Reiter RJ, Cabrera J, Sainz RM, Mayo JC, Manchester LC, Tan DX (1999b). Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and Parkinsonism. Ann NY Acad Sci. 890: 471-485.
96. Reiter RJ, Croft CM, Johnson JE Jr, King TS, Richardson BA, Vaughan GM et al. (1981). Age-associated reduction in nocturnal melatonin levels in female rats. Endocrinology. 109: 1295-1297.
97. Reiter RJ, Manchester LC, Tan DX (2010b). Neurotoxins: free radical mechanisms and melatonin protection. Curr Neuropharmacol. 8: 194-210.
98. Reiter RJ, Pablos MI, Agapito TT, Guerrero JM (1996). Melatonin in the context of the free radical theory of aging. Ann NY Acad Sci. 786: 362-378.
99. Reiter RJ, Paredes SD, Korkmaz A, Manchester LC, Tan DX (2008). Melatonin in relation to the "strong" and "weak" versions of the free radical theory of aging. Adv Med Res. 53: 119-129.
100. Reiter RJ, Paredes SD, Manchester LC, Tan DX (2009). Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol. 44: 175-200.
101. Reiter RJ, Richardson BA, Johnson LY, Ferguson BM, Dinh DT (1980). Pineal melatonin rhythm: reduction in aging Syrian hamsters. Science. 210: 1372-1373.
102. Reiter RJ & Tan DX (2002). Role of CSF in the transport of melatonin. J Pineal Res. 33: 61.
103. Reiter RJ & Tan DX (2003). What constitutes a physiological level of melatonin. J Pineal Res. 34: 79-80.
104. Reiter RJ, Tan DX, Fuentes-Broto L (2010a). Melatonin: a multitasking molecule. Progr Brain Res. 181: 127-151.
105. Reiter RJ, Tan DX, Kim SJ, Manchester LC, Qi W, Garcia JJ et al. (1999a). Augmentation of indices of oxidative damage in lifelong melatonin deficient rats. Mech Ageing Dev. 110: 157-173.
106. Reiter RJ, Tan DX, Osuna C, Gitto E (2000). Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci. 7: 444-458.
107. Reiter RJ, Vaughan MK, Blask DE (1975). Possible role of the cerebrospinal fluid in the transport of pineal hormones in mammals. In: Knigge KM, Scott DE, Kobayashi H, Ishii S, editors. Brain-Endocrine Interaction II. The Ventricular System., Karger, Basel, pp 337-354.
108. Ressmeyer AR, Mayo JC, Zelosko V, Sainz RM, Tan DX, Poeggeler B et al. (2003). Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxy-kynuramine. Redox Rep. 8: 205-213.
109. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V et al. (2004). Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 36: 1-9.
110. Rosales-Corral S, Reiter RJ, Tan DX, Ortiz GG, Lopez-Armas G (2010). Functional aspects of redox control during neuroinflammation. Antioxid Redox Signal. 13: 193-247.
111. Rosen J, Than NN, Koch D, Poeggeler B, Laatsch H, Hardeland R (2006). Interactions of melatonin and its metabolites with ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J Pineal Res. 4: 374-381.
112. Sack RL, Lewy AJ, Erb DL, Vollmer WM, Singer CM (1986). Human melatonin production decreases with age. J Pineal Res. 3: 379-388.
113. Samantaray S, Das A, Thakore NP, Matzelle DD, Reiter RJ, Ray SK et al. (2009). Therapeutic potential of melatonin in traumatic central nervous system injury. J Pineal Res. 47: 134-142.
114. Sanchez-Barcelo EJ, Mediavilla MD, Tan DX, Reiter RJ (2010). Clinical uses of melatonin: evaluation of clinical trials. Curr Med Chem. 17: 2070-2096.
115. Savica R, Rocca WA, Ahlskog JE (2010). Where does Parkinson disease start? Arch Neurol. 67: 798-801.
116. Schapira AH (2010). Complex I: inhibitors, inhibition and neurodegeneration. Exp Neurol. 224: 331-335.
117. Schmid M (2009). Iron chelation therapy in MDS: what have we learnt recently? Blood Rev. 23(Suppl 1): S21-25.
118. Seifman MA, Adamides AA, Nguyen PN, Vallance SA, Cooper DJ, Kossmann T et al. (2008). Endogenous melatonin increases in cerebrospinal fluid of patients after severe traumatic brain injury and correlates with oxidative stress and metabolic disarray. J Cerebr Blood Flow Metab. 28: 684-696.
119. Shah A, Garzon-Mundi T, Mahajan R, Duenas VJ, Quinones-Hinojosa A (2010). Animal models of neurological disease. Adv Exp Med Biol. 671: 23-40.
120. Sharma R, McMillan CR, Niles LP (2007). Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease. J Pineal Res. 43: 245-254.
121. Sheridan MN & Reiter RJ (1970). Observations on the pineal system in the hamster. I. Relations of the superficial and deep pineal to the epithalamus. J Morphol. 131: 153-161.
122. Sheridan MN, Reiter RJ, Jacobs JJ (1969). An interesting anatomical relationship between the hamster pineal gland and the ventricular system of the brain. J Endocrinol. 45: 131-132.
123. Skinner DC & Malpaux B (1999). High melatonin concentrations in ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology. 140: 4399-4405.
124. Smith JA, Mee TJX, Barnes ND, Thornburn RJ, Barnes JLC (1976). Melatonin in serum and cerebrospinal fluid. Lancet. 2: 425.
125. Stankov B, Fraschini F, Reiter RJ (1991). Melatonin binding sites in the central nervous system. Brain Res Rev. 16: 245-256.
126. Stascia P, Paneth P, Rosiak JM (2000). Hydroxyl radical reaction with melatonin molecule: a computational study. J Pineal Res. 29: 125-127.
127. Stascia P, Wanski P, Rosiak JM (1998). Melatonin as a hydroxyl radical scavenger. J Pineal Res. 25: 65-66.
128. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ (1993). Melatonin: a potent, hydroxyl radical scavenger. Endocr J. 1: 57-60.
129. Tan DX, Manchester LC, Reiter RJ, Plummer BF, Limson J, Weintraub ST et al. (2000). Melatonin directly scavenges hydrogen peroxide: a potentially new metabolic pathway of melatonin biotransformation. Free Radic Biol Med. 29: 1177-1185.
130. Tan DX, Manchester LC, Reiter RJ, Qi W, Hanes MA, Farley NJ (1999a). High physiological levels of melatonin in bile of mammals. Life Sci. 65: 2523-2529.
131. Tan DX, Manchester LC, Reiter RJ, Qi WB, Zhang M, Weintraub ST et al. (1999b). Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochem Biophys Acta. 1472: 206-214.
132. Tan DX, Manchester LC, Sanchez-Barcelo E, Mediavilla MD, Reiter RJ (2010). Significance of high levels of endogenous melatonin in mammalian cerebrospinal fluid and in the central nervous system. Curr Neuropharmacol. 8: 162-168.
133. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ (2007). One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species. J Pineal Res. 42: 28-42.
134. Tapias V, Cannon JR, Greenamyre JT (2010). Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. J Neurosci Res. 88: 420-427.
135. Tapias V, Escames G, Lopez LC, Lopez A, Camacho E, Carrion MD et al. (2009). Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in Parkinson mice. J Neurosci Res. 87(13): 3002-3010.
136. Teter B (2004). ApoE-dependent plasticity in Alzheimer's disease. J Mol Neurosci. 25: 167-175.
137. Tocharus J, Khonthun C, Chongthammakun S, Gonitrapong P (2010). Melatonin attenuates methamphetamine-induced over expression of pro-inflammatory cytokines in microglial cell lines. J Pineal Res. 48: 347-352.
138. Tricoire H, Locatelli A, Chemineau P, Malpaux B (2002). Melatonin enters cerebrospinal fluid through the pineal recess. Endocrinology. 143(1): 84-90.
139. Turjanski AG, Rosenstein RE, Estrin DA (1998). Reactions of melatonin and related indoles with free radicals: a computational study. J Med Chem. 41: 3684-3689.
140. Turjanski AG, Saenz DA, Doctorovich F, Estrin DA, Rosenstien RE (2001). Nitrosation of melatonin by nitric oxide: a computational study. J Pineal Res. 33: 31-36.
141. Uban KA, Sliwowska JL, Lieblich S, Ellis LA, Yu WL, Weinberg J et al. (2010). Prenatal alcohol exposure reduces the proportion of newly-produced neurons and glia in the dentate gyrus of the hippocampus in female rats. Horm Behav, in press.
142. Vaughan GM, Pelham RW, Pang SF, Loughlin LL, Wilson KM, Sandock KL et al. (1976). Nocturnal elevation of plasma melatonin and urinary 5-hydroxyindole acetic acid in young men; attempts at modification by brief changes in environmental lighting and sleep and by autonomic drugs. J Clin Endocrinol Metab. 42: 752-764.
143. Velkov ZA, Velkov YZh, Galunska BT, Paskalev DN, Tadjer AV (2009). Melatonin: quantum-chemical and biochemical investigation of antioxidant activity. Eur J Med Chem. 44: 2834-2839.
144. Vidrio E, Jung H, Anastasio C (2008). Generation of hydroxyl radicals from dissolved transition metals in surrogate lung fluid solutions. Atmos Environ. 42: 4369-4379.
145. Vigh B & Vigh-Teichman I (1988). Comparative neurohistology and immunocytochemistry of the pineal complex with special reference to the CSF-contacting neuronal structures. Pineal Res Rev. 6: 1-65.
146. Wang X (2009). The anti-apoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther. 15: 345-357.
147. Wang XC, Zhang J, Yu X, Han L, Zhou ZT, Zhang Y et al. (2005). Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat. Sheng Li Xue Bao. 57: 7-12.
148. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF (2007). Glia as the "bad guys" implications for improving clinical pain control and the clinical utility of opoids. Brain Behav Immun. 21: 131-146.
149. Wojcik M, Burzynska-Pedziwiatr I, Wozniak LA (2010). A review of natural and synthetic antioxidants important for health and longevity. Curr Med Chem, in press.
150. Wood-Allum C & Shaw PJ (2010). Motor neurone disease: a practical update on diagnosis and management. Clin Med. 10: 252-258.
151. Wu YH & Swaab DF (2005). The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res. 38: 145-152.
152. Yap LP, Garcia JV, Han D, Cadenas E (2009). The energy-redox axis in aging and age-related neurodegeneration. Adv Drug Deliv Rev. 61: 1283-1298.
153. Zavodnik IB, Domanski AV, Lapshina EA, Bryszewska M, Reiter RJ (2006). Melatonin directly scavenges free radicals generated in red blood cells and a cell-free system: chemiluminescence measurements and theoretical calculations. Life Sci. 79: 391-400.
154. Zawilska JB, Skene DJ, Arendt J (2009). Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep. 61: 383-410.
155. Zhang H, Squadrito GL, Uppu R, Pryor WA (1999). Reaction of peroxynitrite and melatonin: a mechanistic study. Chem Res Toxicol. 12: 526-534.